Non-responders: Not losing weight on Wegovy or other GLP-1 drugs? You are not alone

In clinical trials, most participants taking Wegovy or Mounjaro to treat obesity lost an average of 15% to 22% of their body weight — up to 50 pounds or more in many cases. But roughly 10% to 15% of patients in those trials were “nonresponders” who lost less than 5% of their body weight.

Now that millions of people have used the drugs, several obesity experts told The Associated Press that perhaps 20% of patients — as many as 1 in 5 — may not respond well to the medications. It’s a little-known consequence of the obesity drug boom, according to doctors who caution eager patients not to expect one-size-fits-all results.

“It’s all about explaining that different people have different responses,” said Dr. Fatima Cody Stanford, an obesity expert at Massachusetts General Hospital

Genetics, hormones and variability in how the brain regulates energy can all influence weight — and a person’s response to the drugs, Stanford said. Medical conditions such as sleep apnea can prevent weight loss, as can certain common medications, such as antidepressants, steroids and contraceptives.

Related on the SLP

Soaring obesity rates: By 2035, more than half of the world’s 8 billion people are predicted to be obese Wegovy and Ozempic: How do GLP-1 weight-loss drugs work?

Viewpoint: RFK Jr. touts AI to guide health care…but searches using the technology he champions expose him as scientifically illiterate

Viewpoint: ‘Bureaucratic and economic obstacles’ to agricultural biotechnology: Europe creeps into the 21st century, but blocks remain

Viewpoint: How the anti-abortion movement twists medical facts and promotes science misinformation

…

Despite such cautions, patients are often upset when they start getting the weekly injections but the numbers on the scale barely budge.

This is an excerpt. Read the original post here